Bristol Changes Up R&D But Not Backing Down On Oncology
The appointment of oncologist Thomas Lynch to succeed Francis Cuss as Chief Scientific Officer suggests the biopharma won’t be straying too far from its current focus on developing cancer drugs.
You may also be interested in...
At ASCO, Bristol-Myers-Squibb's new Chief Scientific Officer Thomas Lynch highlighted key R&D priorities for advancing the company's cancer pipeline and staying ahead of its competitors.
The event that the oncology market has been waiting for has arrived. FDA approved Merck’s PD-1 inhibitor Keytruda for first-line treatment of non-small cell lung cancer, a paradigm-changing event that opens up the largest sales segment for immuno-oncology.
Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.